Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands.

abstract：:In combination cancer immunotherapies, consideration should be given to designing treatment schedules that harmonize with the immune system's natural timing. An efficacious temporally programmed combination therapy of extended half-life interleukin 2 (eIL2), tumor targeting antibody, and interferon (IFN) α was recentl...

journal_title：Oncoimmunology

authors： Rothschilds A,Tzeng A,Mehta NK,Moynihan KD,Irvine DJ,Wittrup KD

更新日期：2019-02-19 00:00:00

abstract：:We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-es...

journal_title：Oncoimmunology

authors： Kebenko M,Goebeler ME,Wolf M,Hasenburg A,Seggewiss-Bernhardt R,Ritter B,Rautenberg B,Atanackovic D,Kratzer A,Rottman JB,Friedrich M,Vieser E,Elm S,Patzak I,Wessiepe D,Stienen S,Fiedler W

更新日期：2018-04-18 00:00:00

abstract：:Macrophage infiltration is a hallmark in the majority of solid tumors. Our studies demonstrated that macrophages that infiltrate human renal cells carcinoma (RCC) display markedly enhanced expression and activity of 15-lipoxygenase-2 (15-LOX2). Obtained data suggest that enhanced lipoxygenase activity in tumor-associa...

journal_title：Oncoimmunology

authors： Kusmartsev S

更新日期：2012-03-01 00:00:00

abstract：:DNA damage responses have been proposed as a gatekeeper to block tumorigenesis. We identify unexpected mechanisms whereby ATM-mediated pathway interacts with NFκB inflammatory cascades, leading to upregulation of integrin-αbβ3 on chemoresistant tumor cells. The integrin-αbβ3 is responsible for impeding tumor-specific ...

journal_title：Oncoimmunology

authors： Jinushi M

更新日期：2012-05-01 00:00:00

abstract：:Rehmannia glutinosa polysaccharide (RGP) has shown an activation of immune cells in vitro. However, the immune stimulatory effect of RGP in a mouse in vivo is not well studied. In this study, we examined the effect of RGP on dendritic cell (DC) activation and anticancer immunity in vivo. Treatments of RGP in C56BL/6 m...

journal_title：Oncoimmunology

authors： Xu L,Kwak M,Zhang W,Zeng L,Lee PC,Jin JO

更新日期：2017-05-12 00:00:00

abstract：:Immune responses have been elicited by a variety of cancer vaccines, but seldom induce regressions of established cancers in humans. As a novel therapeutic immunization strategy, we tested the hypothesis that multiple cytokines/chemokines secreted early in secondary responses ex-vivo might mimic the secretory environm...

journal_title：Oncoimmunology

authors： Valentine FT,Golomb FM,Harris M,Roses DF

更新日期：2017-10-30 00:00:00

abstract：:Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes...

journal_title：Oncoimmunology

authors： Lévesque S,Pol JG,Ferrere G,Galluzzi L,Zitvogel L,Kroemer G

更新日期：2019-04-03 00:00:00

abstract：:Due to their constant exposure to inhaled antigens, lungs represent a particularly immunosuppressive environment that limits excessive immune responses; however, cancer cells can exploit this unique environment for their growth. We previously described the ability of aerosolized CpG-ODN combined with Poly(I:C) (TLR9 a...

journal_title：Oncoimmunology

authors： Le Noci V,Sommariva M,Tortoreto M,Zaffaroni N,Campiglio M,Tagliabue E,Balsari A,Sfondrini L

更新日期：2016-09-20 00:00:00

abstract：:We identified a critical role for receptor for advanced glycation end products (RAGE) in the intratumoral accumulation of myeloid-derived suppressor cells (MDSCs) during pancreatic carcinogenesis. The absence of RAGE markedly delayed neoplasia and limited MDSC accumulation in mice expressing an oncogenic variant of Kr...

journal_title：Oncoimmunology

authors： Vernon PJ,Zeh Iii HJ,Lotze MT

更新日期：2013-05-01 00:00:00

abstract：:Aberrantly glycosylated tumor antigens represent promising targets for the development of anti-cancer vaccines, yet how glycans influence immune responses is poorly understood. Recent studies have demonstrated that GalNAc-glycosylation enhances antigen uptake by dendritic cells as well as CD4+ T-cell and humoral respo...

journal_title：Oncoimmunology

authors： Madsen CB,Pedersen AE,Wandall HH

更新日期：2013-04-01 00:00:00

abstract：:Kynurenine formation by tryptophan-catabolic indoleamine-2,3-dioxygenase 1 (IDO1) plays a key role in tumor immune evasion and inhibition of IDO1 is efficacious in preclinical models of breast cancer. As the response of breast cancer to immune checkpoint inhibitors may be limited, a better understanding of the express...

journal_title：Oncoimmunology

authors： Dewi DL,Mohapatra SR,Blanco Cabañes S,Adam I,Somarribas Patterson LF,Berdel B,Kahloon M,Thürmann L,Loth S,Heilmann K,Weichenhan D,Mücke O,Heiland I,Wimberger P,Kuhlmann JD,Kellner KH,Schott S,Plass C,Platten M,Gerhä

更新日期：2017-01-03 00:00:00

abstract：:The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select for more aggressive disease, meaning that patients may not gain ...

journal_title：Oncoimmunology

authors： Simeone E,Grimaldi AM,Festino L,Giannarelli D,Vanella V,Palla M,Curvietto M,Esposito A,Palmieri G,Mozzillo N,Ascierto PA

更新日期：2017-01-19 00:00:00

abstract：:Recent data suggest that T-cell reactivity against tumor-specific neo-antigens may be central to the clinical efficacy of cancer immunotherapy. The development of personalized vaccines designed to boost T-cell reactivity against patient specific neo-antigens has been proposed largely on the basis of these findings. Wo...

journal_title：Oncoimmunology

authors： van Buuren MM,Calis JJ,Schumacher TN

更新日期：2014-05-14 00:00:00

abstract：:LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as ...

journal_title：Oncoimmunology

authors： Nestvold J,Wang MY,Camilio KA,Zinöcker S,Tjelle TE,Lindberg A,Haug BE,Kvalheim G,Sveinbjørnsson B,Rekdal Ø

更新日期：2017-06-16 00:00:00

abstract：:Neutrophil extracellular traps (NETs) are part of the innate immune defense against microbes, but their contribution to several non-infectious inflammatory conditions has recently been unraveled. We demonstrate that NETs accumulate in the peripheral circulation in tumor-bearing mice, causing systemic inflammation and ...

journal_title：Oncoimmunology

authors： Cedervall J,Dimberg A,Olsson AK

更新日期：2015-10-29 00:00:00

abstract：:Human papillomavirus (HPV) infection is one of the most important etiologic causes of oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients with HPV-negative cancers. However, little is known about the possible causes...

journal_title：Oncoimmunology

authors： Partlová S,Bouček J,Kloudová K,Lukešová E,Zábrodský M,Grega M,Fučíková J,Truxová I,Tachezy R,Špíšek R,Fialová A

更新日期：2015-01-30 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon ...

journal_title：Oncoimmunology

authors： Hargadon KM

更新日期：2015-08-12 00:00:00

abstract：:Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...

journal_title：Oncoimmunology

authors： Tsai AK,Davila E

更新日期：2016-01-15 00:00:00

abstract：:Although the proteasome inhibitor bortezomib has significantly improved the survival of patients with multiple myeloma (MM), the disease remains fatal as most patients eventually develop progressive disease. Recent data indicate that MM cells can evade bortezomib-induced cell death by undergoing autophagy as a consequ...

journal_title：Oncoimmunology

authors： Carlsten M,Namazi A,Reger R,Levy E,Berg M,St Hilaire C,Childs RW

更新日期：2018-11-02 00:00:00

abstract：:Recent studies of human pancreatic cancer challenge the mouse model-derived notion that the pancreas is a site of immune privilege. A heavy infiltration of CD8+ T cells expressing programmed cell death 1 (PD-1) and smaller numbers of myeloid cells and regulatory T cells provides rationale for the clinical evaluation o...

journal_title：Oncoimmunology

authors： Pillarisetty VG

更新日期：2014-08-03 00:00:00

abstract：:Vaccines in combination with chemotherapy have been shown to be safe in different tumor types. We investigated the immunological activity of the TroVax® vaccine in combination with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM). In this first line, open-label, single-arm, phase 2 study, pati...

journal_title：Oncoimmunology

authors： Lester JF,Casbard AC,Al-Taei S,Harrop R,Katona L,Attanoos RL,Tabi Z,Griffiths GO

更新日期：2018-09-07 00:00:00

abstract：:Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (...

journal_title：Oncoimmunology

authors： Deng WW,Mao L,Yu GT,Bu LL,Ma SR,Liu B,Gutkind JS,Kulkarni AB,Zhang WF,Sun ZJ

更新日期：2016-10-07 00:00:00

abstract：:Chronic inflammation can result from inadequate engagement of resolution mechanisms, mainly accomplished by specialized pro-resolving mediators (SPMs) arising from the metabolic activity of lipoxygenases (ALOX5/15) on ω-6 or ω-3 essential polyunsaturated fatty acids (PUFA). We previously demonstrated that formyl pepti...

journal_title：Oncoimmunology

authors： Prevete N,Liotti F,Illiano A,Amoresano A,Pucci P,de Paulis A,Melillo RM

更新日期：2017-02-21 00:00:00

abstract：:HSP110 is induced by different stresses and, through its anti-apoptotic and chaperoning properties, helps the cells to survive these adverse situations. In colon cancers, HSP110 is abnormally abundant. We have recently showed that colorectal cancer (CRC) patients with microsatellite instability (MSI) had an improved r...

journal_title：Oncoimmunology

authors： Berthenet K,Boudesco C,Collura A,Svrcek M,Richaud S,Hammann A,Causse S,Yousfi N,Wanherdrick K,Duplomb L,Duval A,Garrido C,Jego G

更新日期：2016-04-22 00:00:00

abstract：:The elicitation of efficient antitumor immune responses requires the optimal activation of tumor-associated dendritic cells (DCs). Our comparison of the effect of various immunostimulatory treatments on DCs revealed that the best predictor of the success of immunotherapy is not the activation of existing DC population...

journal_title：Oncoimmunology

authors： Kuhn S,Ronchese F

更新日期：2013-11-01 00:00:00

abstract：:Circulating fibrocytes were reported to represent a novel myeloid-derived suppressor cell (MDSC) subset and they were also proposed to be involved in the tumor immune escape. This novel fibrocyte subset had a surface phenotype resembling non-monocytic MDSCs (CD14-CD11chiCD123-) and exhibited immunomodulatory roles. Mo...

journal_title：Oncoimmunology

authors： Gunaydin G,Kesikli SA,Guc D

更新日期：2015-05-27 00:00:00

abstract：:Searching for biomarkers that associated with the acquired resistance of malignant cells to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies is crucial to improve the clinical benefits of these therapeutic agents. We have recently demonstrated that molecular alterations in both oncogenic and imm...

journal_title：Oncoimmunology

authors： Garrido G,Rabasa A,Sánchez B

更新日期：2013-12-01 00:00:00

abstract：:Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

journal_title：Oncoimmunology

authors： Edris B,Weiskopf K,Weissman IL,van de Rijn M

更新日期：2012-10-01 00:00:00

abstract：:Programmed death ligand 1 (PD-L1) expression represents a mechanism of immune escape by inhibiting T cell immunity. This study systematically evaluated the expression of PD-L1, spatial distribution of CD3+ immune cells and the relationship of both factors to survival in nasopharyngeal carcinoma (NPC) patients. A total...

journal_title：Oncoimmunology

authors： Zhu Q,Cai MY,Chen CL,Hu H,Lin HX,Li M,Weng DS,Zhao JJ,Guo L,Xia JC

更新日期：2017-04-27 00:00:00